| Oct 16 |
Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.
|
| Oct 11 |
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Oct 10 |
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum
|
| Oct 9 |
Jaguar Health Inc (JAGX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Financial ...
|
| Oct 8 |
Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial
|
| Oct 2 |
Jaguar’s diarrhoea drug shows benefit in Phase III breast cancer subgroup
|
| Oct 1 |
Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer
|
| Sep 26 |
Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients ...
|
| Sep 25 |
Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
|
| Sep 24 |
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch
|
